Rhythm Pharmaceuticals Inc.
RYTM
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.93B
Close$
$-23.81
120.5% downside
Current Fair Value
120.5% downsideOvervalued by 120.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.93 Billion |
|---|---|
| Enterprise Value | $7.77 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.11 |
| Beta | 1.88 |
| Outstanding Shares | 68,592,661 |
Return
| Return on Equity | -96.97% |
|---|---|
| Return on Assets | -48.19% |
| Return on Invested Capital | -59.90% |
Valuation & Multiples
| P/E Ratio | -37.18 |
|---|---|
| PEG | -650.33 |
| Price to Sales | 38.67 |
| Price to Book Ratio | 38.67 |
| Enterprise Value to Revenue | 32.37 |
| Enterprise Value to EBIT | -41.33 |
| Enterprise Value to Net Income | -37 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | -0.46 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.81
Average shareholder expectationRevenue Estimate
$67.66 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.68
Average shareholder expectationRevenue Estimate
$83.90 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 13.32% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.42%▼ 93.59% |
|---|---|
| Total Invested | $1.24B▼ 80.71% |
| Investors Holding | 91▼ 200.00% |
ESG Score
No data
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...